P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: Potential for accelerated viral drug resistance?

AIDS

Volumn 15, Issue 11, 2001, Pages 1353-1358

  Jones, Kevin ^a   Bray, Patrick G ^a   Khoo, Saye H ^a   Davey, Ross A ^b   Meaden, E Rhiannon ^a   Ward, Stephen A ^a   Back, David J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Antiretroviral therapy; CD 4; Cell sorting; FACS; HIV drug resistance; Pharmacokinetics; Protease inhibitors

Indexed keywords

CARRIER PROTEIN; ELACRIDAR; GLYCOPROTEIN P; INDINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG; VERAPAMIL; VERLUKAST;

ARTICLE; CELL LEVEL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG UPTAKE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS MUTANT; VIRUS REPLICATION;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NELFINAVIR; P-GLYCOPROTEIN; RITONAVIR; SAQUINAVIR;

EID: 0035958776     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200107270-00004     Document Type: Article

References (32)

1. HIV-1 protease inhibitors
2. Human immunodeficiency virus type-1 protease inhibitors: Therapeutic successes and failures, suppression and resistance
3. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein
4. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
5. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells
6. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
7. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes
8. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells
9. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
10. The multidrug resistance protein 1: A functionally important activation marker for murine Th1 cells
11. Effect of ABC transporters on HIV-1 infection: Inhibition of virus production by the MDR1 transporter
12. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
13. Continuous culture of human lymphoblasts from peritoneal blood of a child with acute leukemia
14. Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukemic lymphoblasts
15. Drug resistance mechanisms and MRP expression in response to epirubuicine treatment in a human leukemia cell line
16. N-[2-(dimethylaminoethyl]acridine-4-carboxamide to circumvent three multidrug resistance phenotypes in vitro
17. Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukeamia cells
18. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug
19. Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum
20. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport
21. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates
22. Structural, mechanistic and clinical aspects of MRP1
23. Recovery of replication competent HIV despite prolonged suppression of plasma viraemia
24. Evidence for late stage compartmentalization of HIV-1 resistance mutations between lymph node and peripheral blood mononuclear cells
25. Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART
26. Differential activity of P-glycoprotein in normal blood lymphocyte subsets
27. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein
28. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
29. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes
30. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype
31. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome
32. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture